Date | Time | Source | Headline | Symbol | Company |
06/04/2024 | 1:08PM | iHub Newswire | FeaturedElement79 Gold Corp Continues Fostering Local Community Engagement | | |
06/03/2024 | 4:15PM | GlobeNewswire Inc. | Communiqué de presse : ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients […] | EU:SAN | Sanofi |
06/03/2024 | 4:15PM | GlobeNewswire Inc. | Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 | EU:SAN | Sanofi |
06/03/2024 | 4:15PM | GlobeNewswire Inc. | Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 | EU:SAN | Sanofi |
05/31/2024 | 6:00AM | GlobeNewswire Inc. | Communiqué de presse : Sanofi lance son plan mondial 2024 d’actionnariat salarié | EU:SAN | Sanofi |
05/31/2024 | 6:00AM | GlobeNewswire Inc. | Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan | EU:SAN | Sanofi |
05/31/2024 | 6:00AM | GlobeNewswire Inc. | Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan | EU:SAN | Sanofi |
05/31/2024 | 1:05AM | GlobeNewswire Inc. | Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD | EU:SAN | Sanofi |
05/31/2024 | 1:05AM | GlobeNewswire Inc. | Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD | EU:SAN | Sanofi |
05/31/2024 | 1:05AM | GlobeNewswire Inc. | Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD | EU:SAN | Sanofi |
05/31/2024 | 1:05AM | GlobeNewswire Inc. | Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO | EU:SAN | Sanofi |
05/31/2024 | 1:00AM | GlobeNewswire Inc. | Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation | EU:SAN | Sanofi |
05/31/2024 | 1:00AM | GlobeNewswire Inc. | Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2 | EU:SAN | Sanofi |
05/31/2024 | 1:00AM | GlobeNewswire Inc. | Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation | EU:SAN | Sanofi |
05/30/2024 | 9:01AM | GlobeNewswire Inc. | Press Release: Sanofi completes acquisition of Inhibrx, Inc. | EU:SAN | Sanofi |
05/30/2024 | 9:01AM | GlobeNewswire Inc. | Press Release: Sanofi completes acquisition of Inhibrx, Inc. | EU:SAN | Sanofi |
05/30/2024 | 9:01AM | GlobeNewswire Inc. | Communiqué de presse : Sanofi finalise l’acquisition d’Inhibrx, Inc. | EU:SAN | Sanofi |
05/27/2024 | 1:00AM | GlobeNewswire Inc. | Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma | EU:SAN | Sanofi |
05/27/2024 | 1:00AM | GlobeNewswire Inc. | Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma | EU:SAN | Sanofi |
05/27/2024 | 1:00AM | GlobeNewswire Inc. | Communiqué de presse : La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantation | EU:SAN | Sanofi |
05/21/2024 | 1:30AM | GlobeNewswire Inc. | Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration | EU:SAN | Sanofi |
05/21/2024 | 1:30AM | GlobeNewswire Inc. | Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IA | EU:SAN | Sanofi |
05/21/2024 | 1:30AM | GlobeNewswire Inc. | Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration | EU:SAN | Sanofi |
05/20/2024 | 4:54PM | GlobeNewswire Inc. | Sanofi: Information concerning the total number of voting rights and shares - April 2024 | EU:SAN | Sanofi |
05/20/2024 | 4:54PM | GlobeNewswire Inc. | Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2024 | EU:SAN | Sanofi |
05/20/2024 | 2:15PM | GlobeNewswire Inc. | Communiqué de presse : Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent® dans le traitement de la BPCO | EU:SAN | Sanofi |
05/20/2024 | 2:15PM | GlobeNewswire Inc. | Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM | EU:SAN | Sanofi |
05/20/2024 | 2:15PM | GlobeNewswire Inc. | Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM | EU:SAN | Sanofi |
05/13/2024 | 1:00AM | GlobeNewswire Inc. | Communiqué de presse : Sanofi investit plus d’un milliard d’euros supplémentaires dans la production de médicaments en France, en plus des 2,5 milliards d’euros déjà engagés dans de grands projets de souveraineté sanitaire | EU:SAN | Sanofi |
05/13/2024 | 1:00AM | GlobeNewswire Inc. | Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty | EU:SAN | Sanofi |